MAY - 2023LIFE SCIENCES REVIEW6CONTENTSVertical Analysis22Three C's to Enable Continuous Development and Manufacturing for Small Molecule Active Pharmaceutical IngredientNick Thomson, Executive Director Chemical Research and Development, PfizerAccelerating drug development of novel targeted therapies through histology-agnostic oncology clinical trialsHua Gong, M.D., Ph.D, Senior Vice President, Global Head of Translational Medicine and Clinical Biomarker,Zai Lab20How Allogeneic Stem Cell Therapies Can Transform Prospects in Inherited Retinal DiseasesGil Carrasquinho, VP Head of Cell Therapy, Santen2528The Evolving Landscape of Clinical TrialSanjeev Seenath, Manager, R&D, Principal Scientist, West Pharmaceutical Services18CXO INSIGHTSCXO INSIGHTSInnovation in Neurodegeneration16The New Age of Medical AffairsDr Sarah Tregenza, PhD, BSc (Hons), APAC Oncology Medical Affairs Director, Pierre Fabre Group, and Matthew Britland,Founder and Medical Director, PharmedSciences
< Page 5 | Page 7 >